Sign In
Buy SDZNY
$79.34
-0.468 (-0.586%)
At Close: Jun 03, 2026
Sandoz announces nominations to the Board of Directors and leadership change
01:00am, Tuesday, 05'th Mar 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming An
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
01:00am, Monday, 04'th Mar 2024
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integr
Sandoz enters $265 mln settlement agreement in U.S. price-fixing case
01:22am, Thursday, 29'th Feb 2024
Swiss generic and biosimilar manufacturer Sandoz on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
01:00am, Thursday, 29'th Feb 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal a
Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
09:54pm, Thursday, 08'th Feb 2024
BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five
Sandoz announces changes in the Board of Directors
01:15am, Thursday, 01'st Feb 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual Gene
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
01:00am, Wednesday, 31'st Jan 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® bio
Sandoz to buy eye drug Cimerli in $170 million deal
01:18am, Monday, 22'nd Jan 2024
Sandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for $170 million.
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
01:00am, Monday, 22'nd Jan 2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approv
South Africa's Aspen Pharmacare to buy Sandoz's China business
02:36am, Monday, 04'th Dec 2023
Aspen Pharmacare will buy the Chinese business of Swiss group Sandoz , including commercialisation rights and intellectual property for some established products and those in the pipeline, for up to 9
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
01:00am, Tuesday, 21'st Nov 2023
Basel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 m
Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028
10:40am, Saturday, 11'th Nov 2023
Sandoz is a global leader in the generics and biosimilars sector, with a strong position in the off-patent medicines market. The company recently listed and plans to aggressively pursue a slice of the
Novartis Raises Outlook After Sandoz Generics Spinoff
06:24am, Tuesday, 24'th Oct 2023
Novartis CEO Vas Narasimhan discusses third-quarter results with the company lifting its profit forecast for a third time as he calls the drugmaker a pure-play innovative medicines “powerhouse.” H
Novartis: Better Margin Visibility Ex-Sandoz
12:48am, Friday, 06'th Oct 2023
Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started tradi
SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today
11:33am, Wednesday, 04'th Oct 2023
Sandoz (OTCMKT: SDZNY ) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let's get into everything investors need to know about Sandoz below!
